Dainippon Sumitomo Pharma America, Inc.’s NDA for lurasidone for the treatment of acute schizophrenia has been accepted for review by the FDA. The NDA was submitted on December 30, 2009 and will receive a standard review. “We are pleased that the lurasidone NDA has been accepted for review by the FDA,” said Masayo Tada, president and chief executive officer, Dainippon Sumitomo Pharma Co., Ltd. “We look forward to the potential lurasidone may bring as it represents our commitment to developing...